Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

ss for the year ended June 30, 2011 compared to the net loss for the year ended June 30, 2010 was primarily attributable to a decrease in revenue recognized under Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca as a result of the successful completion of the research collaboration portion of the agreements.

RevenueRevenues in the quarter ended June 30, 2011 were $0.2 million, compared to $0.7 million for the same period in 2010.  For the year ended June 30, 2011, revenues were $1.5 million, compared to $14.2 million for year ended June 30, 2010.  

Costs and ExpensesFor the quarter ended June 30, 2011, total operating expenses were $4.7 million compared to $4.9 million for the comparable quarter of 2010.  For the year ended June 30, 2011, total operating expenses were $15.1 million compared to $17.2 million for the year ended June 30, 2010. The decreases in operating expenses for the respective periods is the result of reducing staffing levels pursuant to Palatin's strategic decision announced in September 2010.

Cash positionPalatin's cash and cash equivalents were $18.9 million as of June 30, 2011, compared to cash, cash equivalents and investments of $8.9 million at June 30, 2010, with current liabilities of $2.8 million as of June 30, 2011 compared to $2.4 million as of June 30, 2010.  

Palatin believes, based on its current operating plan, that its cash and cash equivalents will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST Palatin will host a conference call and webcast on September 22, 2011 at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments.  Individuals interested in listening to the conference call live can dial 1-800-281-7970 (domestic) or 1-913-312-0671 (international), pass code 9488233.  The webcas
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... held full service global investment bank specializing in ... industry note featuring Spherix. The report, ... Senior Analyst at Chardan, was published on March ...
(Date:4/1/2015)... National recruitment firm Slone Partners is pleased ... of Sales at Optimal Medicine, an international digital health ... brings over 20 years experience in healthcare information technology ... including Dell Services Healthcare, Medsphere Systems and McKesson. ... for accomplishing the goals Optimal Medicine had for this ...
(Date:3/31/2015)... VANCOUVER , March 31, 2015  /PRNewswire/ - ESSA ... today that it has filed with the Food and ... Drug ("IND") application related to the Company,s proposed clinical ... the IND application is required in order for ESSA ... The IND application is a complete ...
(Date:3/31/2015)... March 31, 2015  Sonoa Health, a health tech ... has developed a world-first consumer health portal, Health&, which ... wearable devices and more. Today, the Company ... its CEO, who brings to the table more than ... has included working closely with the biggest names in ...
Breaking Biology Technology:Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3Slone Partners Fills Head of Sales at Optimal Medicine 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 3ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 4Investment Banker Appointed CEO of Australian Health Tech Start-Up 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 3
... -- increase of 110% from prior year , , ... KNSY ), a leading medical technology company that provides innovative solutions ... the results for its second quarter and first six months of ... Record EPS of $0.44, representing ...
... The Brazilian Ministry of Agriculture has authorized Dow AgroSciences ... Insect Protection technology. This authorization was given ... Dow AgroSciences also announced that it plans to be ... of corn hybrids with this technology in the future."This ...
... The Binding Site Limited,("The Binding Site" or the ... the publication of the first,international guidelines recommending first-line ... multiple myeloma, a cancer of cells in the ... The guidelines were written on ...
Cached Biology Technology:Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 2Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 3Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 4Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 5Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 6Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 7Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 8Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 9Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 10Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 11Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 12Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 13Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 14Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 15Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 16Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 17Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 18Dow AgroSciences Receives Approval for Cultivation of HERCULEX(R) I Corn in Brazil 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 3International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 4International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 5International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 6International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 7
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group issues ... (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one of ... on their experience with the Wocket in multiple scenarios and ... Whole Foods and other retailers, making both debit and credit ... also says, "If the company meets their plans in ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... their way, cheetahs, lions, elephants, camels and other large wild ... "If we only have 10 minutes to present this idea, ... and evolutionary biology at Cornell. "But if people hear the ... much as we have. Right now, we are investing all ...
... A team of engineers from Washington University in St. ... removed bioaerosols -- airborne biological particulate matter -- from ... new generation of hybrid filters. , The bioaerosols identified ... lifeguards who had become ill with hypersensitivity pneumonitis, a ...
... a defensive, protective reaction. This ancestral and automatic behavior ... predator. A new study published in Psychophysiology finds that ... a threat. The mere picture of an injured or ... images, the study's participants froze as their heart rate ...
Cached Biology News:Proposal would allow wild animals to roam North America 2Proposal would allow wild animals to roam North America 3Device traps, disables harmful bacteria 2When in danger humans are similar to a deer in the headlights 2
... Consists of the LVF-HL, LVF-CUVADPT, FHS-LVF, and ... high-pass and low-pass Linear Variable Filters to ... an adjustable center wavelength and adjustable bandpass. ... (~90%) and blocking band (99.8%). These ...
... of the LVF-UV-HL, LVF-CUV-ADP, FHS-LVF and CVD-Diffuse ... low-pass Linear Variable Filters to create the ... center wavelength and adjustable bandpass. Each filter ... blocking band (99.8%). These filters -- ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Request Info...
Biology Products: